Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Cancer Immunol Res. 2019 Oct 15;7(12):2052–2064. doi: 10.1158/2326-6066.CIR-19-0234

Figure 5. Reduced expression of MET in mouse mammary cancer cells suppresses metastatic tumor expansion in the lung.

Figure 5.

(A) Relative Met mRNA expression in E0771-LG and HML2 cells compared with their parental (Prnt) cells (n=6). *P<0.01 versus parental, Student’s t test. (B) Relative Met mRNA expression in E0771-LG cells expressing tetracycline inducible shRNA against Met (shM#1, shM#2) or control non-silencing shRNA (shCont) cultured with doxycycline for 4 days (n=4). *P<0.05 versus day 0, Student’s t test. (C) Cell proliferation measured by MTT assay and expressed as a ratio to doxycycline (Dox) untreated E0771-LG:shCont cells (n=7). ns; not significant. (D) Metastatic tumor load in the lungs of C57BL/6 mice injected with E0771-LG expressing inducible shRNA (shCont, shMet#1, shMet#2) and treated with or without Dox from day 4 after tumor injection (green arrows) to the endpoints (n=5/group). *P<0.05 versus Dox–, Student’s t test. (E) Bioluminescence images of mice shown in D at the experimental endpoint (day 14; shCont and shMet#1 or day 16; shMet#2). (F) Representative H&E stained sections prepared from the lung at day 14 (shCont and shMet#1) or 16 (shMet#2) after tumor injection. Scale bar: 200 μm. (G) Average size of foci in the lungs at day 14 (shCont and shMet#1) or 16 (shMet#2) post-tumor injection (n=5). *P<0.05 versus Dox–, Student’s t test. Results are mean±SEM.